A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

Phase 3 Completed 445 enrolled Eli Lilly and Company

RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight and have osteoarthritis (OA) of the knee. The study will lasts about 77 weeks.

Timeline

Start: 2023-08-01
Primary completion: 2025-11-14
Completion: 2025-11-14

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Retatrutide	Protein / enzyme biologic	—	Subcutaneous

A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

Summary

Timeline

Drugs

Indications